Inari Medical, Inc. (NARI)

I did a search on "DVT" and went onto sites within the first number of pages of search results that were obvious hospital systems (approximately 30 sites) that went into details of DVT treatments, including Cedar-Sinai, George Washington, Mayo, Hopkins, Penn, Stanford, Inova, UCDavis, UofM, Northwestern, UPMC, Cleveland Clinic and a number of others, even onto sites that were medically related like the CDC, WebMD, NHS and NIH (even Wikipedia). Of all the sites, ONLY A SINGLE ONE mentioned a mechanical thrombectomy as a treatment (Penn) and Wikipedia had a one-liner, recommended "in rare cases".

What I'm getting at:
- NARI has a lot to do in getting their customers to get the word out and even mention the procedure and gain traction in the treatment of DVT.
- NARI seems to have made huge strides, despite it not being a mainstream treatment
- NARI marketing s7cks... should hire a digital marketer, someone that copies, modifies and suggests customer webpages allowing the publishing of a new page easier instead of relying and waiting for someone else to do it; someone to modify and submit edits to the medical information providers on the internet.

amazing, blew it out of the water.

- revenue 144% over last year
- 2x forecast for this year
- earnings crossed over to positive
- huge margins
+ entering new European market
+ 2 new products

I think we'll see $199 before the end of the year

There is 50 M outstanding shares, so 2 M is not much of dilution.
They are profitable, they have 179 M cash and only 29 M debt.
Why this offering, they do not need money? It could be some acquisition.
Any second offering with intention to grow business is a wise decision.

what i got out of the call:
procedure is super safe, super effective above anything else.
replenishment product pipeline seems stable and established, increased due to new product introductions.
european foothold established, especially in western europe.
a pipeline of tangential new products can be expected to be released Q4 through the 1H of next year, in addition to flowsaver.
TAM related to Covid induced clots was 11% in Q2 and decreasing from Q1, down to 4% recently, yet total TAM increased...
which means (unfortunately) the significant Q3 spike we're seeing in Covid now is going to be on top of the increase in "normal"/target (non-Covid) procedures.

Wow!

This company must have multi-billion dollar product. MC=1.7 billion...

Talk about potential for growth...

Good Luck and do your due diligence always...

You bet the high valuation is justified !!!

113% yoy revenue growth ... beats both top and bottom line ... 13c vs 5c and 57.4M vs 55M revs ... cash increased from $164M to $174M.

Full year guidance increased from 234M to 245M.

For those who are uninitiated with IPOs...

Usual IPO only issue 10-20% of company and then there is lock out period of 3-6 months where no insiders can sell. In about a year 50-80% will be floated with secondary from the company once IPO is successful. Secondary is better since large institutions will be interested in buying large shares of stock. In most cases, they just sell it open market to get float up to 80%...

42.4M *42=17.8 billion...

Good Luck to all and do your due diligence always...

YES!
revenue growing triple digits, topped the range of expectations, 2.5x YoY.
increased margins
increased guidance outlook
FDA approval granted on new product

... I'll hold. I know it shouldn't be a CPI dependent stock, but the way i've been timing sales and buys, i'll just hold this one for a while...

After listening to the Healthcare Conference posted on Feb. 24th, a few takeaways I got out of it:
5% of eligible patients were treated for DVT which leaves huge "marketshare" gains to be had. No debt, already profitable, working on educating and opening treatment centers and already showing YoY multiples of revenue. Reminds me of DXCM from 4-5 years ago, where they are first to market and leaders in treatment leading to multiples of growth as adoption of their product is realized. Just started and not tapped any international sales; a whole new market to be tapped, first concentrating on western Europe. Fingers crossed, I just can't help thinking this stock will explode and show multiples of returns for at least the next 3 years.